SCHEMBL2685237

SCHEMBL2685237

O=[N+]([O-])c1ccc(/C=C(\c2ccccc2)c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.61
CES1 P23141 1/20 0.61
BCHE P06276 1/20 0.58
MAOB P27338 1/20 0.58
PTGS2 P35354 4/20 0.54
CYP1B1 Q16678 1/20 0.54
BRAF P15056 1/20 0.53
FBP1 P09467 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
POLB P06746 1/20 0.51
MAPK1 P28482 1/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HSP90AA1 P07900 1/20 0.50
MAPT P10636 1/20 0.50
OPRK1 P41145 1/20 0.50
KMT2A Q03164 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ESR1 P03372 1/20 0.50
PRMT1 Q99873 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2685238 1.00 CES2 (0.61) CES2CES1BCHEMAOBPTGS2
SCHEMBL27942881 0.98 BCHE (0.59) CES2CES1BCHEMAOBPTGS2
SCHEMBL2685107 0.92 CES2 (0.53) CES2CES1BCHEMAOBPTGS2
SCHEMBL9972511 0.92 ALDH1A1 (0.53) CES2CES1BCHEMAOBPTGS2
SCHEMBL2685106 0.92 CES2 (0.53) CES2CES1BCHEMAOBPTGS2
SCHEMBL12533780 0.88 MEN1 (0.66) CES2CES1BCHEMAOBPTGS2
SCHEMBL19439752 0.86 ESR1 (0.66) CES1PTGS2FBP1TDP1MAPK1
SCHEMBL5434503 0.86 ESR1 (0.66) CES1PTGS2FBP1TDP1MAPK1
SCHEMBL5685314 0.86 ESR1 (0.66) CES1PTGS2FBP1TDP1MAPK1
SCHEMBL2685832 0.83 P4HB (0.53) CES2CES1BCHEMAOBPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155382-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2014-06-05 US disclosed
US-20140155382-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2014-06-05 US disclosed
US-20140155382-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2014-06-05 US disclosed
EP-2651924-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2013-10-23 EP disclosed
WO-2012083164-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
US-20120115918-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2012-05-10 US disclosed
US-20120115918-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2012-05-10 US disclosed
US-20120115918-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115918-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CES2 626/4885CES1 396/4885BCHE 2845/4885
US-20140155382-A1 ANTI-VIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS CES2 626/4885CES1 396/4885BCHE 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.